Ipca Labs.
Ipca Labs. Q1 FY27 Results & Concall Highlights
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: order book.
The short version
Ipca Laboratories expects overall consolidated business growth of around 14% to 16% for the current financial year FY27, revised upward from earlier guidance of 12% to 13%. - Domestic formulation business grew 13% in Q1 FY27; chronic segment grew 17.2%, acute segment 8.9%, outperforming the market. - Export business grew 34% in Q1 FY27, with generic business growing 27%, and institutional generic business reporting exceptional growth of 107% due to shipment timing. - Unichem portfolio delivered 9% growth, with U.S. Overall consolidated revenue growth guidance for FY27 revised upward to 14%-16% from earlier 12%-13%.
From Ipca Labs.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Ipca Laboratories expects overall consolidated business growth of around 14% to 16% for the current financial year FY27, revised upward from earlier guidance of 12% to 13%.
- Domestic formulation business grew 13% in Q1 FY27; chronic segment grew 17.2%, acute segment 8.9%, outperforming the market.
- Export business grew 34% in Q1 FY27, with generic business growing 27%, and institutional generic business reporting exceptional growth of 107% due to shipment timing.
- Unichem portfolio delivered 9% growth, with U.S. business growing 27% and Brazil showing strong 52% growth.
- Ipca projects medium-term EBITDA margin improvement to around 26-30% for Ipca and 25% overall for consolidated entities over 2-3 years.
- Biotech investments targeting 7 biosimilar candidates with clinical trials progressing; expected revenue impact starting FY29–FY30.
- U.S. business plans 4-5 new product filings annually, with expectations of consistent growth around 15-17%.
Profitability & Margins
See what Ipca Labs. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major investments are focused on the biotech segment, with around 7 candidates in the pipeline and capacity to work on 3-4 products annually.
- Current year planned biotech investment is approximately INR 100 crores for piloting facilities and R&D.
- Additional capacity expansion in biotech may be needed within 1-2 years.
- Capacity expansion is ongoing for European and U.S. markets, including controlled and extended-release formulations at the Pithampur facility.
- New API plants are being built at Dewas and Wardha due to capacity constraints at Ratlam.
- Continuous process improvements are underway, including converting intermediates for better efficiency.
- Overall CapEx for the current year is expected to be INR 700-800 crores.
- Investments will also support clinical trials for biosimilars targeting global markets.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ipca Labs. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Ipca Labs. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.4K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ipca Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Ipca Labs. Q1 FY27 results?
Ipca Laboratories expects overall consolidated business growth of around 14% to 16% for the current financial year FY27, revised upward from earlier guidance of 12% to 13%. - Domestic formulation business grew 13% in Q1 FY27; chronic segment grew 17.2%, acute segment 8.9%, outperforming the market. - Export business grew 34% in Q1 FY27, with generic business growing 27%, and institutional generic business reporting exceptional growth of 107% due to shipment timing. - Unichem portfolio delivered 9% growth, with U.S. Overall consolidated revenue growth guidance for FY27 revised upward to 14%-16% from earlier 12%-13%.
What is Ipca Labs. share price analysis?
Ipca Labs. currently shows a below-average growth signal. The stock trades at a P/E of 35.3 with a market cap of ₹48,488 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ipca Labs. planning capital expenditure?
Major investments are focused on the biotech segment, with around 7 candidates in the pipeline and capacity to work on 3-4 products annually. - Current year planned biotech investment is approximately INR 100 crores for piloting facilities and R&D. - Additional capacity expansion in biotech may be needed within 1-2 years. - Capacity expansion is ongoing for European and U.S.
Keep Ipca Labs. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.